4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Biotechnology industry and is headquartered in Novato, United States with about 1,371 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, RARE reported $673M in revenue and ($575M) in net income.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Interactive charts & full statements → Open the RARE valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $673M | $560M | $434M | $363M | — |
| Gross Profit | $564M | $483M | $389M | $335M | — |
| Operating Income (EBIT) | ($535M) | ($536M) | ($569M) | ($649M) | — |
| Net Income | ($575M) | ($569M) | ($607M) | ($707M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $136M | $207M | $160M | $166M | $139M | — |
| Gross Profit | $106M | $178M | $132M | $144M | $110M | — |
| Operating Income (EBIT) | ($169M) | ($113M) | ($171M) | ($108M) | ($143M) | — |
| Net Income | ($185M) | ($129M) | ($180M) | ($115M) | ($151M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.5B | $1.5B | $1.5B | $1.5B | — |
| Total Liabilities | $1.6B | $1.2B | $1.2B | $1.2B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RARE viewer.
About TickerBase · Data methodology & sources